MAPT and Alzheimer disease: Similarly, in a type 2 diabetes mellitus mouse model, SF (5.64 μmol/kg/day for 28 days) administration mitigated cognitive decline and reduced pathological hallmarks of AD, such as Aβ-oligomers, Aβ 1–42 plaques, and phospho-tau (122).